Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AstraZeneca

BioNTech SE

Novavax

Pfizer

As Covid-19 becomes endemic, rich governments will turn to Novavax to vaccinate people in developing economies. NVAX stock will benefit.

NVAX Stock Is the Most Undervalued Vaccine Maker for Endemic Covid-19

Johnson & Johnson (NYSE: JNJ) only has a few million doses of its COVID-19 vaccine in its inventory even though regulatory authorization could just be weeks away, Reuters reported Wednesday. What Happened: The revelation regarding the vaccine stock was made by Jeffrey Zients, the Biden administration's COVID-19 response coordinator, according to Reuters.

Johnson&Johnson COVID-19 Vaccine Approval Could Be Near But The Company Is Low On Supply

If authorized for emergency use later this month, the White House expects just a few million doses of Johnson & Johnson's coronavirus vaccine candidate in its inventory by the end of February.

Johnson & Johnson's COVID-19 Vaccine Inventory Is Lighter Than Expected

Amazon

Disney

Alphabet

JPMorgan Chase & Co

Microsoft

McDonald's

If you are getting concerned about the speculative nature of the markets, it might be time to take a good look at blue-chip stocks. The post 7 Blue-Chip Stocks That Aren't a Gamble appeared first on InvestorPlace.

7 Blue-Chip Stocks That Aren't a Gamble

Johnson & Johnson won't have "a big inventory" of its Covid vaccine ready ahead of its regulatory clearance expected this month, a Biden official said Wednesday.

J&J has only a few million Covid vaccine doses ready as it nears U.S. launch, Biden official says

J&J's (JNJ) COVID-19 vaccine, if approved, will be the only COVID-19 vaccine to be approved for single administration.

J&J (JNJ) Seeks Conditional Nod for COVID-19 Vaccine in EU

Atea Pharmaceuticals

Legend Biotech

Eli Lilly

Nkarta, Inc.

Roche Holding AG

Avidity Biosciences

Indicative of investors' enthusiasm for new biotechs, the average gain in share price for the top 10 companies of the sector that went public in 2020 now tops 100%.

Biotech Shares Have Soared Since 2020's Wave of IPOs

Ally Financial

Citizens Financial Group

Humana

New Linde PLC

Mastercard

Simon Property Group

T-Mobile US

The bank thinks the broader market could be flat through year's end, but that doesn't mean there won't be big winners.

10 Stock Picks For Investors Worried About Sky-High Tech Valuations, According To Morgan Stanley

Baxter

Bristol-Myers

Cigna

Cisco Systems

Chevron

Barrick Gold

Home Depot

Mondelez

Merck

Procter & Gamble

Raytheon Technologies

UnitedHealth Group

Exxon Mobil

31 Of 50 Stocks Billionaires Best Love Pay Dividends As Of February

Johnson & Johnson has increased its dividend for 58 years straight. The company has a stellar AAA credit rating.

Johnson & Johnson: The Perfect Vaccine For Your Portfolio

J&J's new vaccine could be important in ending the pandemic.

The Important Things to Know About Johnson & Johnson's COVID Vaccine

Moderna

It's simply not an apples-to-apples comparison.

Here's Why You Can't Compare Vaccine Results Between Johnson & Johnson, Pfizer, and Moderna

A huge market awaits if the company can make enough doses.

1 Green Flag and 1 Red Flag for Johnson & Johnson's Vaccine Candidate

How Long Until We Reach Herd Immunity? Expert Timelines Vary

All American adults could potentially be fully vaccinated this year with only Pfizer's and Moderna's vaccines.

Could the U.S. Buying More COVID Vaccines Hurt Johnson & Johnson and Novavax?

JNJ's COVID-19 vaccine showed 66% efficacy. The market appears to have soured on the stock. A vaccine may not have any impact on JNJ financially. It may appear irrational that vaccine results would impact the stock.

Buy Johnson & Johnson Despite Questions Over Its COVID-19 Vaccine

Investors haven't uniformly given companies that have developed vaccines credit for the possibility they could be a long-term source of revenue.

Annual Covid-19 Boosters May Be Needed, J&J CEO Says

Gilead Sciences

Regeneron Pharmaceuticals

These biotechs are developing innovative therapies while doing their part to combat the coronavirus.

3 Best Biotech Stocks to Buy Now

The significant policy change is based on a small study that has not undergone peer review and did not evaluate the vaccine's protection against severe disease, a key metric of success.

South Africa Abandons Oxford-AstraZeneca Covid-19 Vaccine In Favor Of Unapproved Johnson & Johnson Shot

In an interview with CNBC, CEO Alex Gorsky said mutations of the coronavirus will necessitate changes to vaccines, much like annual flu shots.

Key Words: Expect to get COVID-19 shots for years to come, Johnson & Johnson CEO says

People may need to get vaccinated against Covid-19 annually, just like seasonal flu shots, over the next several years, Johnson & Johnson CEO Alex Gorsky told CNBC on Tuesday.

News for Johnson & Johnson Stock (JNJ)